Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease: A Danish prospective population-based cohort study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease : A Danish prospective population-based cohort study. / Attauabi, Mohamed; Poulsen, Anja; Theede, Klaus; Pedersen, Natalia; Larsen, Lone; Jess, Tine; Rosager Hansen, Malte; Kajbæk Verner-Andersen, Marianne; V Haderslev, Kent; Berg Lødrup, Anders; Molazahi, Akbar; Neumann, Anders; Wase, Abdel; Seidelin, Jakob Benedict; Burisch, Johan.

I: Journal of Crohn's and Colitis, Bind 15, Nr. 4, 2021, s. 540–550.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Attauabi, M, Poulsen, A, Theede, K, Pedersen, N, Larsen, L, Jess, T, Rosager Hansen, M, Kajbæk Verner-Andersen, M, V Haderslev, K, Berg Lødrup, A, Molazahi, A, Neumann, A, Wase, A, Seidelin, JB & Burisch, J 2021, 'Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease: A Danish prospective population-based cohort study', Journal of Crohn's and Colitis, bind 15, nr. 4, s. 540–550. https://doi.org/10.1093/ecco-jcc/jjaa205

APA

Attauabi, M., Poulsen, A., Theede, K., Pedersen, N., Larsen, L., Jess, T., Rosager Hansen, M., Kajbæk Verner-Andersen, M., V Haderslev, K., Berg Lødrup, A., Molazahi, A., Neumann, A., Wase, A., Seidelin, J. B., & Burisch, J. (2021). Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease: A Danish prospective population-based cohort study. Journal of Crohn's and Colitis, 15(4), 540–550. https://doi.org/10.1093/ecco-jcc/jjaa205

Vancouver

Attauabi M, Poulsen A, Theede K, Pedersen N, Larsen L, Jess T o.a. Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease: A Danish prospective population-based cohort study. Journal of Crohn's and Colitis. 2021;15(4):540–550. https://doi.org/10.1093/ecco-jcc/jjaa205

Author

Attauabi, Mohamed ; Poulsen, Anja ; Theede, Klaus ; Pedersen, Natalia ; Larsen, Lone ; Jess, Tine ; Rosager Hansen, Malte ; Kajbæk Verner-Andersen, Marianne ; V Haderslev, Kent ; Berg Lødrup, Anders ; Molazahi, Akbar ; Neumann, Anders ; Wase, Abdel ; Seidelin, Jakob Benedict ; Burisch, Johan. / Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease : A Danish prospective population-based cohort study. I: Journal of Crohn's and Colitis. 2021 ; Bind 15, Nr. 4. s. 540–550.

Bibtex

@article{1bcdf1b56fa04d8e81eeecdc2d2d2582,
title = "Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease: A Danish prospective population-based cohort study",
abstract = "BACKGROUND AND AIMS: As no population-based study has investigated the susceptibility and disease course of COVID-19 among patients with inflammatory bowel diseases (IBD), we aimed to investigate this topic in a population-based setting.METHODS: Two cohorts were investigated. First, a nationwide cohort of all IBD patients diagnosed with COVID-19 was prospectively followed to investigate the disease courses of both diseases. Second, within a population-based cohort of 2.6 million Danish citizens, we identified all individuals tested for SARS-CoV-2 to determine the occurrence of COVID-19 among patients with and without IBD and other immune-mediated inflammatory diseases (IMIDs).RESULTS: Between January 28, 2020 and June 2, 2020, a total of 76 IBD patients with COVID-19 were identified in the national cohort and prospectively followed for 35 days (interquartile range (IQR): 25-51). A large proportion (n=19;25%) required a COVID-19-related hospitalization for seven days (IQR: 2-8.5) which was associated with being 65 years or older (odds ratio (OR)=23.80 (95% confidence interval (CI) 6.32-89.63), p<0.01) and presence of any non-IMID comorbidity (OR=8.12 (95% CI 2.55-25.87), p<0.01), but not use of immunomodulators (p=0.52) or biologic therapies (p=0.14). In the population-based study, 8,476 of 231,601 (3.7%) residents tested positive for SARS-CoV-2; however, the occurrence was significantly lower among patients with IBD (62 of the 2,486 patients=2.5%, p<0.01) and other IMIDs (531 of 16,492 patients=3.2%, p<0.01) as compared to patients without IMIDs.CONCLUSION: Patients with IMIDs, including IBD, had a significantly lower susceptibility to COVID-19 than patients without IMIDs and neither immunosuppressive therapies nor IBD activity were associated with the disease course of COVID-19.",
author = "Mohamed Attauabi and Anja Poulsen and Klaus Theede and Natalia Pedersen and Lone Larsen and Tine Jess and {Rosager Hansen}, Malte and {Kajb{\ae}k Verner-Andersen}, Marianne and {V Haderslev}, Kent and {Berg L{\o}drup}, Anders and Akbar Molazahi and Anders Neumann and Abdel Wase and Seidelin, {Jakob Benedict} and Johan Burisch",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn{\textquoteright}s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2021",
doi = "10.1093/ecco-jcc/jjaa205",
language = "English",
volume = "15",
pages = "540–550",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease

T2 - A Danish prospective population-based cohort study

AU - Attauabi, Mohamed

AU - Poulsen, Anja

AU - Theede, Klaus

AU - Pedersen, Natalia

AU - Larsen, Lone

AU - Jess, Tine

AU - Rosager Hansen, Malte

AU - Kajbæk Verner-Andersen, Marianne

AU - V Haderslev, Kent

AU - Berg Lødrup, Anders

AU - Molazahi, Akbar

AU - Neumann, Anders

AU - Wase, Abdel

AU - Seidelin, Jakob Benedict

AU - Burisch, Johan

N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2021

Y1 - 2021

N2 - BACKGROUND AND AIMS: As no population-based study has investigated the susceptibility and disease course of COVID-19 among patients with inflammatory bowel diseases (IBD), we aimed to investigate this topic in a population-based setting.METHODS: Two cohorts were investigated. First, a nationwide cohort of all IBD patients diagnosed with COVID-19 was prospectively followed to investigate the disease courses of both diseases. Second, within a population-based cohort of 2.6 million Danish citizens, we identified all individuals tested for SARS-CoV-2 to determine the occurrence of COVID-19 among patients with and without IBD and other immune-mediated inflammatory diseases (IMIDs).RESULTS: Between January 28, 2020 and June 2, 2020, a total of 76 IBD patients with COVID-19 were identified in the national cohort and prospectively followed for 35 days (interquartile range (IQR): 25-51). A large proportion (n=19;25%) required a COVID-19-related hospitalization for seven days (IQR: 2-8.5) which was associated with being 65 years or older (odds ratio (OR)=23.80 (95% confidence interval (CI) 6.32-89.63), p<0.01) and presence of any non-IMID comorbidity (OR=8.12 (95% CI 2.55-25.87), p<0.01), but not use of immunomodulators (p=0.52) or biologic therapies (p=0.14). In the population-based study, 8,476 of 231,601 (3.7%) residents tested positive for SARS-CoV-2; however, the occurrence was significantly lower among patients with IBD (62 of the 2,486 patients=2.5%, p<0.01) and other IMIDs (531 of 16,492 patients=3.2%, p<0.01) as compared to patients without IMIDs.CONCLUSION: Patients with IMIDs, including IBD, had a significantly lower susceptibility to COVID-19 than patients without IMIDs and neither immunosuppressive therapies nor IBD activity were associated with the disease course of COVID-19.

AB - BACKGROUND AND AIMS: As no population-based study has investigated the susceptibility and disease course of COVID-19 among patients with inflammatory bowel diseases (IBD), we aimed to investigate this topic in a population-based setting.METHODS: Two cohorts were investigated. First, a nationwide cohort of all IBD patients diagnosed with COVID-19 was prospectively followed to investigate the disease courses of both diseases. Second, within a population-based cohort of 2.6 million Danish citizens, we identified all individuals tested for SARS-CoV-2 to determine the occurrence of COVID-19 among patients with and without IBD and other immune-mediated inflammatory diseases (IMIDs).RESULTS: Between January 28, 2020 and June 2, 2020, a total of 76 IBD patients with COVID-19 were identified in the national cohort and prospectively followed for 35 days (interquartile range (IQR): 25-51). A large proportion (n=19;25%) required a COVID-19-related hospitalization for seven days (IQR: 2-8.5) which was associated with being 65 years or older (odds ratio (OR)=23.80 (95% confidence interval (CI) 6.32-89.63), p<0.01) and presence of any non-IMID comorbidity (OR=8.12 (95% CI 2.55-25.87), p<0.01), but not use of immunomodulators (p=0.52) or biologic therapies (p=0.14). In the population-based study, 8,476 of 231,601 (3.7%) residents tested positive for SARS-CoV-2; however, the occurrence was significantly lower among patients with IBD (62 of the 2,486 patients=2.5%, p<0.01) and other IMIDs (531 of 16,492 patients=3.2%, p<0.01) as compared to patients without IMIDs.CONCLUSION: Patients with IMIDs, including IBD, had a significantly lower susceptibility to COVID-19 than patients without IMIDs and neither immunosuppressive therapies nor IBD activity were associated with the disease course of COVID-19.

U2 - 10.1093/ecco-jcc/jjaa205

DO - 10.1093/ecco-jcc/jjaa205

M3 - Journal article

C2 - 33035299

VL - 15

SP - 540

EP - 550

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 4

ER -

ID: 251180558